Chimeric Therapeutics Ltd. 2023 SR
The report details Chimeric Therapeutics' commitment to ESG principles and the World Economic Forum's Stakeholder Capitalism Metrics for the 2023 fiscal year. The company focuses on developing curative cell therapies while maintaining high governance standards and ethical business practices. Key highlights include a board composition with 67% female representation and a 100% carbon offset for business flights. Despite its small size, the company significantly increased its research and development investment to over $14.4 million to advance its clinical pipeline.
Company: Chimeric Therapeutics Ltd.
Sector: Professional & technical services
Country: Australia
Year: 2023
Type: SR
Pages: 10
Back to company
Chimeric Therapeutics Ltd.
ESG Report
The report details Chimeric Therapeutics' commitment to ESG principles and the World Economic Forum's Stakeholder Capitalism Metrics for the 2023 fiscal year. The company focuses on developing curative cell therapies while maintaining high governance standards and ethical business practices. Key highlights include a board composition with 67% female representation and a 100% carbon offset for business flights. Despite its small size, the company significantly increased its research and development investment to over $14.4 million to advance its clinical pipeline.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jul 1, 2022 - Jun 30, 2023
Fiscal Year
2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Workplace Fatalities
Employees